Market Research Logo

Global Lung Cancer Therapeutics Market 2016-2020

About Lung Cancer Therapeutics

Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes almost 85%-90% of the total diagnosed cases. It grows and spreads quite slowly.

Technavio’s analysts forecast the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global lung cancer therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent lung cancer therapeutics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Lung Cancer Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • F. Hofmann-La Roche
  • Eli Lilly
  • AstraZeneca
  • Pfizer
  • Celgene
Other prominent vendors
  • Abbvie
  • Aetna
  • Agennix
  • Allergan
  • Amgen
  • ARIAD Pharmaceuticals
  • Astellas Pharma
  • Betta Pharmaceuticals
  • BeyondSpring Pharmaceuticals
  • BioNumerik Pharmaceuticals
  • Boehringer Ingelheim
  • Boston Biomedical
  • Bristol-Myers Squibb
  • Celldex
  • CTI BioPharma
  • Eisai
  • GlaxoSmithKline
  • GTx
  • Helsinn
  • Hutchison Medipharma
  • Ionis Pharmaceuticals
  • Kadmon Corporation
  • MabVax
  • Merck
  • Novartis
  • NovaRx Corporation
  • OncoGeneX
  • Ono Pharmaceutical
  • OSE Immunotherapeutics
  • OSI Pharmaceuticals
  • Peregrine
  • PharmaMar
  • Pierre Fabre
  • Qiagen
  • Recombio
  • Samsung Bioepis
  • Sanofi
  • SFJ Pharmaceuticals
  • Spectrum Pharmaceuticals
  • Sumitomo Dainippon Pharma
  • Synta
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical
  • Xcovery
Market driver
  • Growing demand for targeted therapies
  • For a full, detailed list, view our report
Market challenge
  • Growing popularity of alternative therapeutics
  • For a full, detailed list, view our report
Market trend
  • Emergence of nanomedicine platform for the treatment of lung cancer
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Lung Cancer Therapeutics Market 2016-2020

Technavio recognizes the following companies as the key players in the global lung cancer therapeutics market: F. Hofmann-La Roche, Eli Lilly, AstraZeneca, Pfizer, and Celgene.

Other Prominent Vendors in the market are: Abbvie, Aetna, Agennix, Allergan, Amgen, ARIAD Pharmaceuticals, Astellas Pharma, Betta Pharmaceuticals, BeyondSpring Pharmaceuticals, BioNumerik Pharmaceuticals, Boehringer Ingelheim, Boston Biomedical, Bristol-Myers Squibb, Celldex, CTI BioPharma, Eisai, GlaxoSmithKline, GTx, Helsinn, Hutchison Medipharma, Ionis Pharmaceuticals, Kadmon Corporation, MabVax, Merck, Novartis, NovaRx Corporation, OncoGeneX, Ono Pharmaceutical, OSE Immunotherapeutics, OSI Pharmaceuticals, Peregrine, PharmaMar, Pierre Fabre, Qiagen, Recombio, Samsung Bioepis, Sanofi, SFJ Pharmaceuticals, Spectrum Pharmaceuticals, Sumitomo Dainippon Pharma, Synta, Takeda Pharmaceuticals, Teva Pharmaceutical, and Xcovery.

Commenting on the report, an analyst from Technavio’s team said: “The market has witnessed the emergence of nanomedicine, which is likely to have a positive impact on the market. The lipid-based nanoparticles and polymer-based approaches for the drug delivery are gaining traction in the market, owing to the limitations of current technologies. The existing technologies need numerous cells to detect the presence of a tumor. On the other hand, nanotechnology approach could radically lower this requirement, allowing much earlier diagnosis or treatment regimes.”

According to the report, the market has been witnessing an increased demand for immune-based therapies such as checkpoint inhibitors. There are various types of checkpoint inhibitors that target different checkpoints on immune cells. These treatments work by allowing to mount a stronger and effective attack against lung cancer. The traditional chemotherapy approach involves the destruction of cancerous cells as well as nearby benign cells. This will create a lot of side effects and affects the patient compliance.

Further, the report states that the growing popularity of alternative therapeutics are expected to hinder growth prospects in the market. With the increasing side effects of conventional drugs, the individuals are seeking for alternative therapeutics. The increased demand for these therapies is also due to the high cost of lung cancer therapeutics. Some of the alternative therapeutics include mind and body medicines, biology-based practices, energy work, and whole medical systems.

Companies Mentioned

F. Hofmann-La Roche, Eli Lilly, AstraZeneca, Pfizer, Celgene, Abbvie, Aetna, Agennix, Allergan, Amgen, ARIAD Pharmaceuticals, Astellas Pharma, Betta Pharmaceuticals, BeyondSpring Pharmaceuticals, BioNumerik Pharmaceuticals, Boehringer Ingelheim, Boston Biomedical, Bristol-Myers Squibb, Celldex, CTI BioPharma, Eisai, GlaxoSmithKline, GTx, Helsinn, Hutchison Medipharma, Ionis Pharmaceuticals, Kadmon Corporation, MabVax, Merck, Novartis, NovaRx Corporation, OncoGeneX, Ono Pharmaceutical, OSE Immunotherapeutics, OSI Pharmaceuticals, Peregrine, PharmaMar, Pierre Fabre, Qiagen, Recombio, Samsung Bioepis, Sanofi, SFJ Pharmaceuticals, Spectrum Pharmaceuticals, Sumitomo Dainippon Pharma, Synta, Takeda Pharmaceuticals, Teva Pharmaceutical, Xcovery.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Key customer segments of global lung cancer therapeutics market
  • Disease overview
    • Understanding the disease
      • Table Snapshot of lung cancer
    • Economic burden
    • Types of lung cancer
      • Table Types of lung cancer
    • Diagnosis
      • Table Main diagnostic procedures to determine presence of lung cancer
    • Staging of SCLC
      • Table Staging of SCLC
    • Staging of NSCLC
      • Table Illustration of stages of NSCLC disease
    • Key buying criteria
      • Table Key buying criteria for lung cancer therapeutics
      • Table Factors affecting adoption rates of lung cancer therapeutics
  • Pipeline analysis
    • Table Pipeline analysis of key vendors in global lung cancer therapeutics market
    • Table Percentage share of drug candidates by stage of development
    • Table Phase III pipeline portfolio: Global lung cancer therapeutics market
    • Table Phase II pipeline portfolio: Global lung cancer therapeutics market
    • Table Phase I pipeline portfolio: Global lung cancer therapeutics market
  • Market landscape
    • Global lung cancer therapeutics market
      • Table Global lung cancer therapeutics market snapshot
      • Table Analysis of global lung cancer therapeutics market
      • Table Global lung cancer therapeutics market size and forecast 2015-2020 ($ billions)
      • Table Opportunity analysis of global lung cancer therapeutics market
      • Table Opportunity analysis in developed and emerging markets
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by disease type
    • Table Segmentation of global lung cancer therapeutics market by disease type 2015 and 2020
    • Table Life cycle analysis of key segments in global lung cancer therapeutics market 2015
    • NSCLC
      • Table Types of NSCLC
    • Global NSCLC market overview
      • Table Potential drugs/drug candidates in global NSCLC therapeutics market
      • Table Key drivers impacting market growth in NSCLC
      • Table Global NSCLC therapeutics market size and forecast 2015-2020 ($ billions)
      • Table Opportunity analysis in global NSCLC market
    • SCLC
      • Table Key points in SCLC
    • Global SCLC market overview
      • Table Key drivers impacting market growth in SCLC
      • Table Global SCLC therapeutics market size and forecast 2015-2020 ($ billions)
      • Table Opportunity analysis in global SCLC therapeutics market
  • Market segmentation by type of molecule
    • Table Segmentation of global lung cancer therapeutics market by type of molecule 2015
    • Small molecules
    • Biologics
  • Geographical segmentation
    • Table Global lung cancer therapeutics market by geographical segmentation 2015-2020
    • Table Segmentation of global lung therapeutics market based on geography 2015 and 2020
    • Table Lung cancer therapeutics market revenue by geography 2015-2020 ($ billions)
    • Lung cancer therapeutics market in Americas
      • Table Lung cancer therapeutics market in Americas 2015-2020 ($ billions)
      • Table Key trends across various countries in Americas
    • Lung cancer therapeutics market in EMEA
      • Table Lung cancer therapeutics market size and forecast in EMEA 2015-2020 ($ billions)
      • Table Drivers in lung cancer therapeutics market in EMEA
      • Table Key strategic initiatives in various countries in EMEA
    • Lung cancer therapeutics market in APAC
      • Table Lung cancer therapeutics market size and forecast in APAC 2015-2020 ($ billions)
      • Table Key drivers and challenges in APAC
  • Market drivers
    • Growing demand for targeted therapies
      • Table YoY growth rate of Avastin 2015
    • Presence of blockbuster drugs coupled with longer patent exclusivities
      • Table Performance of blockbuster drugs in 2015
      • Table Patent exclusivities of few blockbuster drugs
    • Advancements in identification of molecular biomarkers increasing patient pool
    • Paradigm shifts toward the adoption of checkpoint inhibitors
      • Table Recent launches of checkpoint inhibitors
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Growing popularity of alternative therapeutics
      • Table Alternative therapies for lung cancer therapeutics
    • High costs leading to low adoption rate
      • Table Costs of few lung cancer drugs ($)
    • Adverse effects of drugs
      • Table Force field analysis of drivers and challenges in global lung cancer therapeutics market
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table Trend analysis in global lung cancer therapeutics market
    • Emergence of nanomedicine platform for the treatment of lung cancer
      • Table Key factors driving adoption of nanomedicine
    • Advent of miRNA therapeutics in the treatment of lung cancer
      • Table Factors driving adoption of miRNA therapeutics
    • Growing strategic alliances for late-stage pipeline
      • Table Key deals in global lung cancer therapeutics market
    • Growing approvals in lung cancer therapeutics market
      • Table Recent approvals of lung cancer therapeutics
  • Vendor landscape
    • Competitive scenario
      • Table Competitive analysis in global lung cancer therapeutics market
      • Table Market penetration of various lung cancer therapeutics manufacturers in global (2015)
      • Table Regional analysis of vendors in global lung cancer therapeutics market
      • Table Vendors ranking in global lung cancer therapeutics market
  • Key vendor analysis
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Key highlights
      • Table F. Hoffmann-La Roche: Strength assessment
      • Table F. Hoffmann-La Roche: Strategy assessment
      • Table F. Hoffmann-La Roche: Opportunity assessment
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Geographic segmentation of Avastin by revenue 2015
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Tarceva 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Geographic segmentation of Tarceva by revenue 2015
    • Eli Lilly
      • Table Eli Lilly: Key highlights
      • Table Eli Lilly: Strength assessment
      • Table Eli Lilly: Strategy assessment
      • Table Eli Lilly: Opportunity assessment
      • Table Eli Lilly: YoY revenue and growth rate of Alimta 2013-2015 ($ billions)
      • Table Eli Lilly: Geographic segmentation by revenue of Alimta 2015
      • Table Eli Lilly: YoY and growth rate of Cyramza 2014-2015 ($ millions)
      • Table Eli Lilly: Geographic segmentation by revenue of Cyramza 2015
    • AstraZeneca
      • Table AstraZeneca: Key highlights
      • Table AstraZeneca: Strength assessment
      • Table AstraZeneca: Strategy assessment
      • Table AstraZeneca: Opportunity assessment
      • Table AstraZeneca: YoY revenue and growth rate of Iressa 2013-2015 ($ billions)
      • Table AstraZeneca: Geographic segmentation of Iressa 2013-2015 (% share)
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
      • Table Pfizer: YoY revenue and growth rate of Xalkori 2013-2015 ($ millions)
    • Celgene
      • Table Celgene: Key highlights
      • Table Celgene: Strength assessment
      • Table Celgene: Strategy assessment
      • Table Celgene: Opportunity assessment
      • Table Celgene: YoY revenue and growth rate of Abraxane 2013-2015 ($ millions)
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report